DD · 8-K · 20261103PR000058

Acquisitions and Divestitures

DuPont de Nemours, Inc. · 2026-11-03 · Importance 65 · Surprise 60 · No source text

DuPont completed the sale of its Aramids business to an Arclin subsidiary on April 1, 2026. Consideration included approximately $1.2 billion of pre-tax cash proceeds, subject to customary adjustments, a $300 million principal-amount note receivable, and a non-controlling Arclin equity interest valued at $325 million. The divested business is reported as discontinued operations, and nine-month 2026 proceeds and adjustments from business sales were $1.159 billion.

Key facts

• DuPont completed the sale of its Aramids business on April 1, 2026, for approximately $1.2 billion in pre-tax cash proceeds, subject to customary transaction adjustments, a $300 million note receivable, and a non-controlling equity interest valued at $325 million. source
• The Aramids sale consideration included a non-controlling common equity interest in Arclin valued at $325 million. source
• DuPont expects reimbursement for transition support costs under TSAs to Qnity through year-end 2027 for services and 2040 for site leases, and to the Aramids Business no later than 2028. source
• DuPont faces potential balance-sheet, financial-condition, and operating-results impacts, post-closing adjustments, disputes, or unanticipated costs related to the Aramids Divestiture. source

Impact estimates